A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Plain-language summary
This trial is testing the combination of alectinib (ALK inhibitor) and duvelisib (PI3K inhibitor) for patients with anaplastic large cell lymphoma (ALCL) whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 7 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Alectinib (DRUG): All patients will receive a lead-in cycle (28 days) of alectinib. | Duvelisib (DRUG): After the lead-in cycle of alectinib, in the absence of progressive disease as assessed by PET/CT scan, all patients will then receive two 28-day cycles of alectinib plus duvelisib.
Alectinib, Duvelisib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details